Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bjh.18064 | DOI Listing |
Tohoku J Exp Med
January 2023
Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital.
Lenalidomide (LEN), one of the key drugs in the treatment of myelodysplastic syndromes (MDS) with 5q deletion, as well as multiple myeloma (MM), has various immunomodulatory effects and has been associated with autoimmune diseases, including immune thrombocytopenic purpura (ITP). A 78-year-old man presented with pancytopenia and was diagnosed with MDS with 5q deletion and other chromosomal abnormalities. Two cycles of LEN therapy (one cycle: 10 mg/day for 21 days) resulted in a transient improvement in anemia, followed by MDS progression with severe thrombocytopenia (4 × 10/L) refractory to platelet transfusions.
View Article and Find Full Text PDFBr J Haematol
June 2022
Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Cureus
December 2020
Internal Medicine, Emory University School of Medicine, Atlanta, USA.
A 33-year-old previously healthy Middle Eastern male presented to the emergency department with four weeks of progressively worsening fatigue, dyspnea on exertion, night sweats, and a 10-pound weight loss after suffering a self-limiting viral upper respiratory illness. He was found to be profoundly anemic and thrombocytopenic with normal white blood cell count with a lymphocytic predominance. His anemia was refractory to red blood cell transfusions, to which he developed hyperbilirubinemia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!